Highlights in Advanced Prostate Cancer From the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium A Review of Selected Presentations From the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium • January 30-February 1, 2014 • San Francisco, California Special Reporting on: • Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer (mCRPC): Results of Phase III PREVAIL Study • Antigen Spread and Survival With Sipuleucel-T in Patients With Advanced Prostate Cancer • Results From a Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Orteronel (TAK-700) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) That Has Progressed During or Following Docetaxel-Based Therapy (ELM-PC 5 Trial) • Impact of Prior Radiation Treatment (tx) on Sipuleucel-T (sip-T) Product Parameters in PROCEED Patients (pts) • 1.5-Year Post-Treatment Follow-Up of Radium-223 Dichloride (Ra-223) in Patients With CastrationResistant Prostate Cancer (CRPC) and Bone Metastases From the Phase 3 ALSYMPCA Study • Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients ≥80 Years-Old: Data From PROCEED
PLUS Meeting Abstract Summaries With Expert Commentary by: Daniel J. George, MD Associate Professor of Medicine and Surgery Divisions of Medical Oncology and Urology Duke University Medical Center Durham, North Carolina
ON THE WEB: hematologyandoncology.net Indexed through the National Library of Medicine (PubMed/MEDLINE), PubMed Central (PMC), and EMBASE
SPECIAL MEETING REVIEW EDITION
Table of Contents Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer (mCRPC): Results of Phase III PREVAIL Study
3
Antigen Spread and Survival With Sipuleucel-T in Patients With Advanced Prostate Cancer
4
Results From a Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Orteronel (TAK-700) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) That Has Progressed During or Following Docetaxel-Based Therapy (ELM-PC 5 Trial) 6 Impact of Prior Radiation Treatment (tx) on Sipuleucel-T (sip-T) Product Parameters in PROCEED Patients (pts)
8
1.5-Year Post-Treatment Follow-Up of Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases From the Phase 3 ALSYMPCA Study
9
Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients ≥80 Years-Old: Data From PROCEED
11
Highlights in Advanced Prostate Cancer From the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary
Daniel J. George, MD 12
2 Clinical Advances in Hematology & Oncology
Volume 12, Issue 4, Supplement 11 April 2014
H I G H L I G H T S I N A D V A N C E D P R O S TAT E C A N C E R F R O M T H E 2 0 1 4 A S C O G E N I T O U R I N A R Y C A N C E R S S Y M P O S I U M
